Klinicheskiy sluchay uspeshnogo lecheniya HER-pozitivnogo disseminirovannogo raka zheludka s polnym i prodolzhitel'nym effektom
- 作者: Vakhabova Y.V1, Filimonyuk A.V1, Lodygina K.S1, Vorontsova K.A1, Lichinitser M.R1
-
隶属关系:
- 期: 编号 18 (2015)
- 页面: 80-85
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288324
- ID: 288324
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The article presents a clinical case of a combined treatment of 35-year old female patient with disseminated stomach cancer and HER2/ neu hyperexpression. The combinations of cisplatin+capecitabine+trastuzumab were used. Against the background of the treatment, complete effect was achieved, the length of time to progression was 35 months, the duration of the complete effect - 27 months. Over all survival was 72 months.
全文:
参考
- Ferlay J., Shin H.R., Bray F., Forman D., Mathers C, Parkin D.M. GLOBOCAN 2008, Cancer Incidence and Mortality Wordwide: IARC Cancer Base № 10 (Internet). Lyon, France: International Agency for Reserch on Cancer; 2010.
- Злокачественные заболевания в России в 2011 году (заболеваемость и смертность) / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2013. 289 с.
- Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007;298:70-82.
- Hofmann M., Stoss O., Shi D., Buttner R., van de Vijver M., Kim W., Ochiai A., Rüschoff J., Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805
- Bang Y.J., van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742): 687-97.
- Narikazu Boku. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12.
- Manish A. Shah. Update on Metastatic Gastric and Esophageal Cancers. J. Clin. Oncol. 2015;33(16):1760-69.
- Herceptin [Trastuzumab] in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer; ClinicalTrials.gov identifier NCT01450696.
- Pertuzumab With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastroesophageal Junction Cancer] study; ClinicalTrials.gov identifier NCT01774786.
- TDM1 vs Taxane in Previously Treated Advanced HER2 Gastric Cancer; ClinicalTrials.gov identifier NCT01641939.
- A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced/ Metastatic Gastric Cancer; ClinicalTrials.gov identifier MO28230.
补充文件
